You are on page 1of 28

Region Sub-region

America Central America

North America

South America

Asia East and South-East Asia

Near and Middle East

Europe Eastern Europe

South-Eastern Europe

. Western & Central Europe Oceania Oceania Note: For the purposes of this report. which differs from no history of medical use. NPS include ketamine.

28 2009 19 .28 2003 19 . 16 0.28 2011 19 .14 2012 15 .28 2005 19 .00 2010 16 .40 2010 16 .19 2012 17 . 25 0. 65 0. 25 0.28 2010 19 . Prevalence Life-time preva Country Survey year Age All Costa Rica 2010 15 . 64 0. 65 0.40 2010-11 15 .60 United States of America 2002 19 .16 1.20 2009 n/a 1.10 2010 15 and above 1. 24 0.28 2004 19 .70 2008 16 .28 2008 19 .20 .28 2000 12th Grade 2001 12th Grade 2002 12th Grade 2003 12th Grade 2004 12th Grade 2005 12th Grade 2006 12th Grade 2007 12th Grade 2008 12th Grade 2009 12th Grade 2010 12th Grade 2011 12th Grade 2012 12th Grade 2013 12th Grade 2014 12th Grade Argentina 2006 16 . 65 0.20 Canada 2004 15 and above 1.00 2007 15 and above 1. 24 0. 24 0.28 2007 19 .28 2006 19 .50 2006 16 .36 El Salvador 2010 17 .30 2008 16 .

64 0.10 2014 15 .64 2011 15 .90 2008 18 .01 2012 University students 0. 40 0.25 2.65 0.19 0.65 0.50 Bolivia 2012 University students 0.64 0.00 Indonesia 2009 11 .60 2011 16 .80 Romania 2010 n/a 0. 24 2008 18 .08 China.65 0.10 .05 Peru 2006 0.65 0.16 2014 11 .18 2012 University students 0.20 0.20 2009 11 -99 2009 11 .17 0.55 2011 15 .16 0.99 2008 11 .30 2014 15 .02 Colombia 2013 12-65 0.65 0. 15 and 17 0.64 2012 15 .20 Chile 2014 15 .16 2012 15 .40 2005 18 . 40 0. 2010 12 .20 2014 11 and above China.26 Ecuador 2009 n/a 0.16 0.65 0. Hong Kong SAR 2007 11 -99 2007 11 .20 2008 11 .16 0.01 2010 12 .30 Thailand 2007 12 .30 2011 15 . 40 0.70 Israel 2005 18 .12 Uruguay 2006 15 .17 0.01 2012 University students 0. 24 2009 18 .60 2014 13 .30 2011 13.90 Ukraine 2011 15 .60 2015 University students 1. Macao SAR 2006 15 .70 2011 15 .25 Brazil 2005 15 .

40 Germany 2009 n/a 0.24 4.20 2010-11 16 .64 1.59 2.80 France 2003 n/a Spain 2010 14 .59 2.18 1.30 2013-14 16 . which differs from other NPS in that it is widely used in hum .24 4.60 2014-15 16 .30 2011-12 16 .24 2.10 2011 15 .50 2011-12 16 .24 2.64 1.20 2008-09 16 .50 2009-10 16 .59 1.00 2012 14 .15 2012 11 .24 4.00 Wales) 2006-07 16 .18 1.59 2.80 2009-10 15 .64 0.40 2010 15 -16 2010 18 .24 3.20 2012-13 16 .59 1.64 4.59 1.00 2012-13 16 .64 1.10 2013 15 .59 2.59 2.30 2007-08 16 .15 2014 11 .50 2013 14 and older 1.20 port. NPS include ketamine.70 2014-15 16 .00 Australia 2007 15 .15 2013 11 .24 2.70 New Zealand 2008 16 .80 United Kingdom 2006-07 16 .59 2.24 4. 2013 15 .30 England 2011 11 .00 2010-11 16 .00 2010 14 and older 1.64 0.30 2007-08 16 .30 2007 12-17 0.70 2013-14 16 .24 3.00 2009-10 16 .24 4.15 2008-09 16 .

50 1.60 0.50 2.40 1.50 2.50 0.60 1.90 0.60 0.90 1.50 0.40 0.10 1.00 0.07 0.50 1.10 1.50 0.50 0.00 0.30 0.30 0.00 0.80 0.30 0.80 1.50 2.60 2.21 0.Prevalence of use of Ketamine* in the general and youth populati Life-time prevalence Past-year prevalence Past month Male Female All Male Female All Male Female 0.20 2.20 0.70 1.00 1.00 0.80 0.60 1.19 0.40 1.53 0.10 1.50 0.70 1.00 0.30 .50 0.21 0.00 0.40 0.60 0.40 0.30 1.20 0.

08 0.04 0.00 0.20 0.03 0.01 0.80 0.18 0.00 0.0.10 0.12 0.10 0.30 0.10 .27 0.00 0.22 0.00 0.10 0.01 0.40 0.21 0.03 0.05 0.11 0.20 0.12 0.20 1.04 0.02 0.18 0.07 0.05 0.10 0.33 0.08 0.05 0.70 0.22 0.50 0.17 0.16 0.05 0.34 0.00 0.10 0.05 0.00 0.00 0.02 0.02 0.25 0.03 0.01 0.00 0.01 0.03 0.13 0.09 0.40 0.30 1.03 0.01 0.20 0.87 0.34 0.40 0.05 0.20 0.08 0.23 0.38 0.02 0.00 0.08 0.30 0.02 0.09 0.30 0.00 0.55 0.10 0.06 0.12 0.02 0.18 0.24 0.05 1.00 0.40 0.90 0.03 0.50 0.56 0.20 0.

50 0.40 0.10 dely used in human and veterinary medicine.40 0.00 0.50 0.00 0.20 1.10 0.10 0.40 0.50 0.70 0.60 0. 0.80 0.20 0.70 0.80 0.20 0.30 0.10 1.90 1. while most NPS have little or .30 0.00 0.00 2.20 0.50 0.70 0.10 0.10 0.00 0.30 2.30 0.10 0.90 0.30 1.30 0.50 0.90 0.80 0.20 0.70 0.40 0.20 0.80 0.80 0.00 0.20 0.70 0.30 1.60 0.80 0.00 0.20 1.60 1.30 0.50 0.70 0.40 0.40 0.20 1.10 0.00 0.20 0.00 0.60 0.20 0.00 0.40 0.50 0.80 0.50 0.90 0.20 0.50 0.30 0.20 0.00 1.50 0.20 0.30 0.80 0.80 3.40 0.40 0.70 0.90 0.90 0.21 0.50 0.60 1.00 0.50 0.25 0.60 0.40 0.

2010 . 2010 Psicoactivas en Argentina 2004 .youth population (per cent) Source ARQ ARQ ARQ Estudio Nacional sobre Consumo de Drogas en Población Estudiantil Universitaria de El Sal ARQ ARQ ARQ ARQ Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2014 Psicoactivas en Argentina 2004 . 2010 Psicoactivas en Argentina 2004 . 2010 ARQ Psicoactivas en Argentina 2004 .2010 Psicoactivas en Argentina 2004 . 2010 Psicoactivas en Argentina 2004 .

Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ ARQ ARQ ARQ Illegal use of drugs and alcohol in Israel 2009: Seventh national epidemiological survey ARQ Illegal use of drugs and alcohol in Israel 2009: Seventh national epidemiological survey ARQ ARQ ARQ .ARQ Quinta Encuesta Nacional a Estudiantes de Enseñanza Media 2011 Quinta Encuesta Nacional a Estudiantes de Enseñanza Media 2011 ARQ Sexto Estudio Nacional Sobre Consumo de Sustancias Psicoactivas en Estudiantes de Ense II Estudio Epidemiológico Andino en la Población Universitaria ARQ Décimo Primer Estudio Nacional de Drogas en Población General 2014 Estudio Nacional de Consumo de Sustancias Psicoactivas en Colombia 2013 ARQ ARQ II Estudio Epidemiológico Andino en la Población Universitaria ARQ Informe ejecutivo: IV Encuesta Nacional de consumo de drogas en la población general del II Estudio Epidemiológico Andino en la Población Universitaria ARQ ARQ VI Encuesta Nacional de Consumo de Drogas en Estudiantes de Enseñanza Media 2014 VI Encuesta Nacional en Hogares sobre consumo de drogas 2014 I Pilot Study on Drug Use among University Students in Uruguay ARQ. Central Registry of Drug Abuse ARQ. Central Registry of Drug Abuse ARQ.

alcool şi droguri GPS – 20 ARQ ARQ Government Government Government Government ARQ SDD Survey SDD Survey SDD Survey SDD Survey National report to EMCDDA ARQ 2010/11 British Crime Survey 2010/11 British Crime Survey 2010/11 British Crime Survey 2010/11 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2011 to 2012 British Crime Survey Drug Misuse: Findings from the 2011 to 2012 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey Drug Misuse: Findings from the 2014 to 2015 British Crime Survey Drug Misuse: Findings from the 2014 to 2015 British Crime Survey ARQ ARQ ARQ ARQ 2010 National Drug Strategy Household Surbey Report ARQ 2007/08 New Zealand Alcohol and Drug Use Survey .Studiul naţional în populaţia generală privind consumul de tutun.

Media 2014 010 DEVIDA .

Region Sub-region Americas North America South America Europe South-Eastern Europe Western & Central Europe Oceania Oceania * Following their international control in 2015. the synthetic cannabinoids JWH cannabinoids which are and those which are not under international control. .

19 4.64 0.16 13.16 Wales) 2010-11 16 . the synthetic cannabinoids JWH-018 and AM-2201 no longer belong to the e which are not under international control. .59 2010-11 16 .10 Latvia 2011 15 .16 10.18 1.50 2011 15 . Prevalence of use o Life-time preva Country Survey year Age All United States of America 2011 19 .64 0.80 2012 18 .60 2010 15 .59 Croatia 2010-11 n/a 1.80 2012 14-18 1.10 2011 15 .30 New Zealand 2013 15+ ontrol in 2015.60 2013 15 .50 Sweden 2012 15 .64 1.24 6.64 2.30 2011 12th Grade 2012 12th Grade 2013 12th Grade 2014 12th Grade Chile 2014 15 .40 2013 15 .64 0.24 2011-12 16 .10 Spain 2010 14 .10 2011 15 .20 Germany 2009 18 .64 0.64 0.30 2010 15 .59 Australia 2013 14 and older 1.

ence of use of Synthetic Cannabinoids* in the general and youth p Life-time prevalence Past-year prevalence Past month Male Female All Male Female All Male Female 6.37 0.20 0.20 0.80 0.00 2.10 1.40 15.75 0.37 1.30 14.40 2.00 0.10 0. in the context of pr .10 0.50 11.60 4.80 2.50 0.50 0.70 1.40 0.70 er belong to the category of new psychoactive substances.00 0. However.10 1.60 6.00 0.10 0.26 1.70 1.10 0.60 0.10 0.90 0.30 0.40 0.40 11.82 1.56 0.50 9.30 7.20 0.10 0.09 12.00 0.90 5.00 0.10 3.

it is not possible to differentiate between t . in the context of prevalence of use surveys.ral and youth population (per cent) Source Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2014 Décimo Primer Estudio Nacional de Drogas en Población General 2014 2012 National Report to the EMCDDA 2013 National Report to the EMCDDA 2013 National Report to the EMCDDA ARQ ESPAD methodological survey ARQ ARQ ARQ 2011 National Report to the EMCDDA Government Government Government Government ARQ Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2011 to 2012 British Crime Survey ARQ 2012/13 New Zealand Health Survey: Drug Module r.

Region Sub-region Americas North America Asia Near and Middle East Europe South-Eastern Europe Western & Central Europe .

MDPV and BZP no of use was included in this table. mephedrone. .Oceania Oceania * Following their international control in 2015.

Prevalence of use o Country Substance Survey year Canada Salvia Divinorum 2011 Salvia Divinorum 2010-11 United States of America Salvia Divinorum 2011 Salvia Divinorum 2014 Salvia Divinorum 2013 Salvia Divinorum 2012 Salvia Divinorum 2011 Salvia Divinorum 2010 Salvia Divinorum 2009 Israel Khat 2008 Khat 2008 Yemen Khat 2006 Croatia Mephedrone 2010-11 Hungary Mephedrone 2011 Ireland and Northern Ireland Mephedrone 2010/11 Mephedrone 2010/11 Latvia Salvia Divinorum 2011 Malta Mephedrone 2011 Ketamine 2009 Finland MDPV 2010 Slovakia Mephedrone 2010 Mephedrone 2010 Spain Piperazines 2010 Piperazines 2011 Piperazines 2012 Piperazines 2013 Mephedrone 2010 Mephedrone 2012 Mephedrone 2013 Salvia Divinorum 2010 Salvia Divinorum 2011 Salvia Divinorum 2012 Salvia Divinorum 2013 Wales) BZP 2010-11 BZP 2010-11 Khat 2010-11 Mephedrone 2011-12 .

mephedrone. Mephedrone 2011-12 Mephedrone 2012-13 Mephedrone 2012-13 Mephedrone 2013-14 Mephedrone 2013-14 Mephedrone 2014-15 Mephedrone 2014-15 BZP 2011-12 Salvia Divinorum 2012-13 Salvia Divinorum 2012-13 Salvia Divinorum 2013-14 Salvia Divinorum 2013-14 New Zealand BZP 2008 BZP 2008 ntrol in 2015. MDPV and BZP no longer belong to the category of new psyc .

10 16 .50 0.40 12 .30 2.10 15 .80 3.30 3.10 0.40 0.50 5.90 1.30 72.80 12th Grade 3.00 n/a 0.80 5.50 2.nce of use of miscellaneous new psychoactive substances* in the g Life-time prevalence Past-year prevalence Age All Male Female All Male Female 15 .10 15 .70 14 . 24 0.10 0.30 15 .30 15-64 0.00 1.90 12th Grade 5. 59 0.64 1.64 0.50 5.00 5.00 15 .30 16 6.18 0.00 32.80 6.20 14-18 0.00 14-18 15-64 0.40 0.40 6.00 14 .70 18 .30 15 .60 n/a 0.10 0.18 12 and above 52.50 0.90 8.30 15-64 0.30 15 .2 est.20 16 .50 12th Grade 5.40 15 .00 0.70 .16 2.80 0.90 0. 64 0.60 2. 69 0.10 0. 1.20 15 . 34 4.18 0.40 0.90 0.30 14-18 0.80 1. 15 . 64 2.30 2. 59 1.10 1. 16 3.40 12th Grade 5.40 2. 59 0.00 19 .20 16 .00 3. 19 1.50 15-64 0.10 16 .50 1.50 0.1 est.00 2.00 14-18 0. 16 4.10 0.50 12th Grade 1.00 0.40 12th Grade 4.

24 6.30 13.17 19.40 4.24 5.60 16 .70 11.30 ory of new psychoactive substances.80 16 .30 1.90 16 .24 3.90 15.24 4.60 6.64 13.59 0.50 17.24 1.59 2.24 1.50 16 . 16 .59 2.40 9. as the data presented here refers to a tim .50 15.50 1.40 5.59 1.30 16 .90 0.10 16 .10 16 .50 16 .50 24.40 0.59 0.20 0.50 16 . However.30 16 .90 16 .30 1.90 16 .60 16 .59 0.20 1.30 3.

20 0.30 0.00 .10 0.00 0.00 0.ances* in the general and youth populations (per cent) Past month All Male Female 1.20 0.20 0.10 0.65 1.10 0.10 0.84 6.00 0.00 0.50 0.20 0.

20 0. info .50 here refers to a time when these substances were not yet controlled internationally. 0.

ral and youth populations (per cent) Source ARQ ARQ Monitoring the Future 2011 Monitoring the Future 2014 Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2013 Overview: Key Findings on Adolescent Drug Use Monitoring the Future 2011 Monitoring the Future 2011 Monitoring the Future 2011 Illegal use of drugs and alcohol in Israel 2009: Seventh national epidemiological survey Illegal use of drugs and alcohol in Israel 2009: Seventh national epidemiological survey Towards Qat Demand Reduction (World Bank) 2012 National Report to the EMCDDA ARQ Drug Prevalence Survey 2010/11: Regional Drug Task Force (Ireland) and Health & Social C Drug Prevalence Survey 2010/11: Regional Drug Task Force (Ireland) and Health & Social C ARQ ARQ ARQ ARQ ARQ 2011 National Report to the EMCDDA Government Government Government Government Government Government Government Government Government Government Government Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2010 to 2011 British Crime Survey Drug Misuse: Findings from the 2011 to 2012 British Crime Survey .

information available on th . Drug Misuse: Findings from the 2011 to 2012 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey Drug Misuse: Findings from the 2014 to 2015 British Crime Survey Drug Misuse: Findings from the 2014 to 2015 British Crime Survey Drug Misuse: Findings from the 2011 to 2012 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2012 to 2013 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey Drug Misuse: Findings from the 2013 to 2014 British Crime Survey 2007/08 New Zealand Alcohol and Drug Use Survey 2007/08 New Zealand Alcohol and Drug Use Survey en these substances were not yet controlled internationally.

t (Northern Ireland) Results t (Northern Ireland) Results .